Business Wire

Ganymed Robotics Announces Appointment of Seasoned Leadership Team to Bring to Market Its Next Generation Surgical Technology

Share

Ganymed Robotics, a developer of computer vision software and robotics technologies for orthopedic surgeons, is happy to announce a series of senior leadership appointments to drive the company’s growth as it prepares for industrialization and commercial launch. The firm has appointed 5 seasoned executives to lead strategic and operational developments across all key functions, ranging from product development to regulatory and market access, finance, human resources and legal. Former companies include ZimmerBiomet, Alphatec, EOS Imaging, Corwave, Beckton Dickinson, Robocath, Médecins Sans Frontières.

The composition of the new Executive Committee exhibits strong expertise in both launching innovative medical devices and scaling medtech companies, as well as gender parity. It is composed of 8 members : Sophie Cahen, CEO and co-founder, Silvère Lucquin, Chief Operating Officer, and Michel Vernizeau, VP R&D, and 5 seasoned new members: Lukas Vancura as VP Product Marketing, Clémentine Liard as VP Quality Assurance and Regulatory Affairs (QARA), Sandra Demol as Human Resources Director, Julien Puaux as VP Finance and Juliette Loget as General Counsel. These additions to the Executive Committee reflect Ganymed’s continued attractiveness for talents of all seniority, and its commitment to bringing its game-changing arthroplasty robot into operating rooms as quickly as possible.

“I am delighted to partner with such talented senior executives who bring to the company their impressive experience and recognized expertise, as we accelerate the development of our revolutionary patented technology platform and prepare for industrialization and launch of our first surgical robotic assistant for knee arthroplasty,” says Sophie Cahen. “The arrival of the leadership team’s newest members is a testimony of the swift growth that Ganymed accomplished over the past 18 months, both on the scientific and operational fronts, and speaks to a team united by a profound sense of shared purpose.”

Ganymed Robotics’ ambition is to democratize access to quality care in hard tissue surgery. The company aims to secure and standardize a complex surgical gesture, so that each patient gets the right, personalized care. The first application is a co-manipulated surgical robotic assistant for total knee arthroplasty (TKA). It has developed a proprietary technology platform built around two disruptive innovations: contactless localization of the bones and human-machine collaborative movement.

Over the past 18 months, Ganymed reached several major milestones, attesting of its ability to efficiently implement its growth strategy: it completed a 36 M€ Series B fundraising round with a high-profile group of healthcare investors, welcomed two world renowned independent members on its Board of Directors, Michel Therin et Mike Lobinsky, doubled the size of its team across all functions to reach 40 persons today, secured strategic partnerships, moved forward with regulatory and marketing developments, won new national and international innovation awards, and ran successful pre-clinical tests. With the arrival of high-profile senior executives on its leadership team, Ganymed is ideally positioned to successfully accelerate the execution of its strategic, industrial, and operational development plan.

About Ganymed Robotics

Ganymed Robotics is a medical device company founded in 2018, developing the next generation of robotic assistance technologies for orthopedic surgery. The company’s mission is to improve patient outcome, surgeon experience, and overall efficiency of care delivery for its target indications. Based in Paris, Ganymed Robotics currently employs 40 people who develop a proprietary technology platform combining computer vision, a branch of artificial intelligence, and mechatronics, in close collaboration with world-class clinicians and advisors. The first application is a robotic surgical assistant for knee arthroplasties, a common and fast-growing intervention associated with high dissatisfaction rates of above 20%. Ganymed Robotics intends to progressively deploy its technology to address several other orthopedics indications. Ganymed Robotics won national and international innovation awards, such as I-Nov, I-Lab, French Tech DeepNum20, French Tech Emergence, Deep Tech Pioneer, EIT Health, Wilco, EIC Accelerator. For more information: www.ganymedrobotics.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press
Strategies & Image (S&I)
Anne Rein
+33 6 03 35 92 05
anne.rein@strategiesimage.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF Declares Dividend for Third Quarter 202530.7.2025 23:20:00 EEST | Press release

IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on October 10, 2025 to shareholders of record as of September 29, 2025. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20250730368333/en/

IFF Appoints Paul J. Fribourg and Jesus B. Mantas to Board of Directors30.7.2025 23:15:00 EEST | Press release

IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Paul J. Fribourg and Jesus B. Mantas to its board of directors, effective immediately. These appointments bring extensive international leadership experience, and industry and strategic insight to IFF as the company continues to advance its innovation agenda and strengthen its market position. “I am delighted that Paul and Jesus are joining the IFF board,” said Kevin O’Byrne, chair of the IFF board. “They bring a strong combination of digital innovation, global market insight and operational excellence. Their experience, leadership and vision will help guide IFF through its next phase of growth as we continue to deliver breakthrough solutions for customers and create long-term value for our stakeholders.” Paul J. Fribourg Fribourg brings more than four decades of global leadership experience in agribusiness, food and investment sectors, and currently serve

Estithmar Holding Reports Record Half-Year Results for 202530.7.2025 20:46:00 EEST | Press release

Revealing an exceptional performance across all key financial metrics, Estithmar Holding Q.P.S.C. announced its financial results for the six-month period ended 30 June 2025, following board approval. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250730991496/en/ Estithmar Holding Reports Record Half-Year Results for 2025 (Graphic: AETOSWire) The company reported revenue of QAR 3.073 billion, an 87% year-on-year increase. Gross profit soared by 134% to QAR 1.054 billion, while EBITDA rose 97% to QAR 732 million compared to H1 2024. Net profit reached QAR 465 million, up 97% year-on-year, while earnings per share (EPS) doubled, reaching QAR 0.130. While Estithmar Holding continues its upward trajectory in its financial and operational indicators across all its financial disclosures, this remarkable leap in results for H1 2025 is mainly attributed to increased revenue through its international expansions across its 4 sectors

Andersen Consulting Expands AI-Enablement Capabilities with Addition of NextGen Invent30.7.2025 16:30:00 EEST | Press release

Andersen Consulting enters into a Collaboration Agreement with NextGen Invent, an AI enablement and technology services company focused on delivering innovative, data-centric solutions, strengthening the organization’s digital transformation platform by integrating advanced data science, AI, and intelligent automation capabilities. Headquartered in the U.S., NextGen Invent brings deep expertise in generative AI, machine learning, data strategy, advanced analytics, digital product development, IoT, and intelligent automation. Their solutions are behind some of the most recognizable brands in the healthcare, financial services, life sciences, and manufacturing industries. With a strong emphasis on innovation, NextGen Invent helps organizations across these industries to accelerate digital maturity, optimize operations, and uncover new opportunities for growth. The company is known for its technology thought leadership and ability to drive business outcomes through intelligent insights. “

Armis Honored with Inaugural Wiz Integrations (WIN) Partner Award30.7.2025 16:00:00 EEST | Press release

Armis, the cyber exposure management & security company, has been recognized by Wiz as a winner in the inaugural WIN awards, earning the WINspiration Award for its outstanding partnership. This recognition highlights Armis' track record of delivering real outcomes for joint customers through the WIN program. Armis, recognized for its commitment to customer success and innovation, brings the power of Armis Centrix™, the Armis Cyber Exposure Management Platform, to WIN, enabling customers to seamlessly integrate Wiz into their existing workflows. This partnership empowers Wiz and Armis to share prioritized security findings with context, including inventory, vulnerabilities, issues and configuration findings. Mutual customers can operationalize the remediation lifecycle by: Gaining deep situational awareness of every asset and its details across the digital landscape Consolidating, contextualizing and prioritizing Wiz findings in Armis based on asset profile and business risk weighting A

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye